Macquarie Group LTD Intellia Therapeutics, Inc. Transaction History

Macquarie Group LTD

$90.3 Billion
Q3 2024

A detailed history of Macquarie Group LTD transactions in Intellia Therapeutics, Inc. stock. As of the latest transaction made, Macquarie Group LTD holds 20,000 shares of NTLA stock, worth $228,200. This represents 0.0% of its overall portfolio holdings.

Number of Shares

20,000

Previous 20,000 -0.0%

Holding current value

$228,200

Previous $447,000 8.05%

% of portfolio

0.0%

Previous 0.0%

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 21, 2023	SELL	$33.21 - $62.69 $15,907 - $30,028	-479 Reduced 2.34%	20,000 $697,000
Q3 2022 Nov 14, 2022	SELL	$53.92 - $71.7 $42,758 - $56,858	-793 Reduced 3.73%	20,479 $1.19 Million
Q4 2021 Feb 11, 2022	SELL	$100.76 - $138.36 $28,918 - $39,709	-287 Reduced 1.33%	21,272 $2.52 Million
Q3 2021 Nov 12, 2021	BUY	$132.37 - $176.78 $96,630 - $129,049	730 Added 3.5%	21,559 $2.89 Million
Q2 2021 Aug 13, 2021	SELL	$60.88 - $161.91 $32,144 - $85,488	-528 Reduced 2.47%	20,829 $3.37 Million
Q1 2021 May 14, 2021	SELL	$46.59 - $83.68 $19,381 - $34,810	-416 Reduced 1.91%	21,357 $1.71 Million
Q2 2020 Aug 11, 2020	BUY	$11.14 - $22.87 $242,551 - $497,948	21,773 New	21,773 $457,000
Q1 2019 May 15, 2019	SELL	$12.79 - $17.62 $3,836 - $5,286	-300 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$11.39 - $27.13 $2,278 - $5,426	200 Added 200.0%	300 $4,000
Q3 2018 Nov 15, 2018	SELL	$25.78 - $32.6 $92,808 - $117,360	-3,600 Reduced 97.3%	100 $3,000
Q2 2018 Aug 14, 2018	BUY	$20.02 - $30.79 $74,074 - $113,923	3,700 New	3,700 $101,000

Others Institutions Holding NTLA

# of Institutions

314

Shares Held

91.5M

Call Options Held

442K

Put Options Held

880K

View Full List

About Intellia Therapeutics, Inc.

Ticker NTLA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,011,800
Market Cap $867M
Description
Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...

More about NTLA

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Macquarie Group LTD, based on Form 13F filings with the SEC.

News

Stay updated on Macquarie Group LTD with notifications on news.

Account

Macquarie Group LTD Intellia Therapeutics, Inc. Transaction History